Australian Biotech Solagran Limited (ASX: SLA) announced that it had received formal documentation from the Russian Ministry of Heath advising that pharmaceutical registration of both its substance Bioeffective® R and the associated medicine Ropren has been finalised.
SLA Price at posting:
45.7¢ Sentiment: LT Buy Disclosure: Held